1. Home
  2. EVAX vs BCDA Comparison

EVAX vs BCDA Comparison

Compare EVAX & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EVAX
  • BCDA
  • Stock Information
  • Founded
  • EVAX 2008
  • BCDA N/A
  • Country
  • EVAX Denmark
  • BCDA United States
  • Employees
  • EVAX N/A
  • BCDA N/A
  • Industry
  • EVAX Biotechnology: Biological Products (No Diagnostic Substances)
  • BCDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • EVAX Health Care
  • BCDA Health Care
  • Exchange
  • EVAX Nasdaq
  • BCDA Nasdaq
  • Market Cap
  • EVAX 8.7M
  • BCDA 7.9M
  • IPO Year
  • EVAX 2021
  • BCDA N/A
  • Fundamental
  • Price
  • EVAX $2.62
  • BCDA $2.63
  • Analyst Decision
  • EVAX Strong Buy
  • BCDA Strong Buy
  • Analyst Count
  • EVAX 3
  • BCDA 1
  • Target Price
  • EVAX $33.33
  • BCDA $25.00
  • AVG Volume (30 Days)
  • EVAX 6.9M
  • BCDA 55.0K
  • Earning Date
  • EVAX 03-26-2025
  • BCDA 03-26-2025
  • Dividend Yield
  • EVAX N/A
  • BCDA N/A
  • EPS Growth
  • EVAX N/A
  • BCDA N/A
  • EPS
  • EVAX N/A
  • BCDA N/A
  • Revenue
  • EVAX $3,295,000.00
  • BCDA $71,000.00
  • Revenue This Year
  • EVAX $9,039.73
  • BCDA N/A
  • Revenue Next Year
  • EVAX $1.47
  • BCDA N/A
  • P/E Ratio
  • EVAX N/A
  • BCDA N/A
  • Revenue Growth
  • EVAX N/A
  • BCDA N/A
  • 52 Week Low
  • EVAX $2.22
  • BCDA $1.63
  • 52 Week High
  • EVAX $22.50
  • BCDA $8.85
  • Technical
  • Relative Strength Index (RSI)
  • EVAX 40.86
  • BCDA 61.81
  • Support Level
  • EVAX $2.30
  • BCDA $2.27
  • Resistance Level
  • EVAX $2.90
  • BCDA $2.78
  • Average True Range (ATR)
  • EVAX 0.98
  • BCDA 0.27
  • MACD
  • EVAX 0.02
  • BCDA 0.02
  • Stochastic Oscillator
  • EVAX 5.28
  • BCDA 77.61

About EVAX Evaxion Biotech

Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: